Alabsi Sarah M, Duval Sue, Sundberg Michael, Williams Donovan, Luepker Russell V, Eder Milton, Van't Hof Jeremy R
University of Minnesota Medical School, Minneapolis MN, USA.
Cardiovascular Division and Lillehei Heart Institute, Department of Medicine, University of Minnesota Medical School, Minneapolis MN, USA.
Prev Med Rep. 2023 Dec 20;37:102571. doi: 10.1016/j.pmedr.2023.102571. eCollection 2024 Jan.
Despite high prevalence of cardiovascular disease (CVD) and CVD risk factors among American Indian or Alaska Native adults (AI/AN), there is little information on aspirin use in this population. This survey-based study seeks to understand prevalence of aspirin use in a sample of AI/AN adults in the Upper Midwestern United States. In-person and telephone based surveys were conducted querying self-reported CVD and CVD risk factors, aspirin use, and aspirin related discussion with clinicians. A total of 237 AI/AN participants were included: mean age (SD) was 60.8 (8.4) years; 143 (60 %) were women; 59 (25 %) reported CVD history. CVD risk factors were common particularly smoking (37 %) and diabetes (37 %). Aspirin use was much higher among those with CVD (secondary prevention, 76 %) than those without (primary prevention, 33 %). Primary prevention aspirin use was significantly associated with age and all CVD risk factors in unadjusted analyses. After adjustment for demographics and CVD risk factors, only age (aRR 1.13 per 5 years, 95 % CI 1.02, 1.25) and diabetes (aRR 2.44, 95 % CI 1.52, 3.92) remained significantly associated with aspirin. Regardless of CVD status, a higher proportion of those taking aspirin reported a conversation about aspirin with their doctor compared to those not taking aspirin. Among participants with no CVD, those who had such a conversation were 2.6 times more likely to use aspirin than those who did not have a conversation (aRR 2.64, 95 % CI 1.58, 4.44). The findings of this study emphasize the importance of the patient-provider relationship for preventive therapy.
尽管美国印第安人或阿拉斯加原住民成年人(AI/AN)中心血管疾病(CVD)及CVD风险因素的患病率很高,但关于该人群使用阿司匹林的信息却很少。这项基于调查的研究旨在了解美国中西部上游地区AI/AN成年人群体中阿司匹林的使用情况。研究通过面对面和电话调查,询问了自我报告的CVD及CVD风险因素、阿司匹林使用情况以及与临床医生关于阿司匹林的讨论。总共纳入了237名AI/AN参与者:平均年龄(标准差)为60.8(8.4)岁;143名(60%)为女性;59名(25%)报告有CVD病史。CVD风险因素很常见,尤其是吸烟(37%)和糖尿病(37%)。患有CVD的人群(二级预防,76%)中阿司匹林的使用率远高于未患CVD的人群(一级预防,33%)。在未经调整的分析中,一级预防中阿司匹林的使用与年龄及所有CVD风险因素显著相关。在对人口统计学和CVD风险因素进行调整后,只有年龄(每5年调整风险比1.13,95%置信区间1.02,1.25)和糖尿病(调整风险比2.44,95%置信区间1.52,3.92)仍与阿司匹林的使用显著相关。无论CVD状态如何,与未服用阿司匹林的人相比,服用阿司匹林的人中报告与医生讨论过阿司匹林的比例更高。在无CVD的参与者中,进行过此类讨论的人使用阿司匹林的可能性是未进行过讨论的人的2.6倍(调整风险比2.64,95%置信区间1.58,4.44)。本研究结果强调了医患关系对预防性治疗的重要性。